Scholarlink

<p>Chronic lymphocytic leukemia (CLL) cells may bear mutations in IGHV genes, the 2%-cutoff allowing to discriminate two subsets, unmutated (U)- or mutated (M)-CLL, with different clinical course. IGHV genes may also incorporate additional ongoing mutations, a phenomenon known as intraclonal diversification (ID). Here, through an original bioinformatic workflow for NGS data, we used the inverse Simpson Index (iSI) as diversity measure among IGHV sequences to dichotomize cases with different ID levels into ID<sub>high</sub> (iSI ≥ 1.2) vs. ID<sub>low</sub> (iSI &lt; 1.2) both in CLL (<i>n</i> = 983) and in other lymphoproliferative disorders (LPD; <i>n</i> = 127). In CLL, ID<sub>high</sub> cases accounted for 14.6%, overrepresented in M-CLL (<i>P</i> = <i>0.0028</i>), while higher percentages were documented in GC-derived LPD. In M-CLL (<i>n</i> = 396), ID<sub>high</sub> patients (<i>n</i> = 69) experienced longer time-to-first treatment than ID<sub>low</sub> patients (<i>P</i> = 0.015), and multivariate analyses (<i>n </i>= 299) confirmed ID as independent variable. IGHV gene mutations of ID<sub>high</sub> cases had molecular signatures indicating ongoing activity of the AID)/Polη-dependent machinery; consistently, ID<sub>high</sub> M-CLL expressed higher levels of AID transcripts than ID<sub>low</sub> M-CLL (<i>P</i> = 0.012). In conclusion, we propose a robust NGS protocol to quantitatively evaluate ID in CLL, demonstrating that: i) all CLL patients presented ID although at various degree; ii) high degree of ID has clinical relevance identifying a M-CLL subset with better outcome.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月18日

查看全文
  • Filippo Vit,
  • Tamara Bittolo,
  • Antonella Zucchetto,
  • Robel Papotti,
  • Erika Tissino,
  • Federico Pozzo,
  • Annalisa Gaglio,
  • Andrea Stacchetti,
  • Eva Zaina,
  • Ilaria Cattarossi,
  • Paola Varaschin,
  • Paola Nanni,
  • Michele Berton,
  • Alessandra Braida,
  • Francesca Maria Rossi,
  • Massimo Degan,
  • Jerry Polesel,
  • Roberta Laureana,
  • Annalisa Chiarenza,
  • Jacopo Olivieri,
  • Annalisa Biagi,
  • Giovanni D’Arena,
  • Marco Rossi,
  • Luca Laurenti,
  • Agostino Tafuri,
  • Pietro Bulian,
  • Alberto Zamò,
  • Ellen Leich,
  • Andreas Rosenwald,
  • Evgeny Arons,
  • Robert Kreitman,
  • Massimo Gentile,
  • Massimiliano Postorino,
  • Francesco Zaja,
  • Francesco Di Raimondo,
  • Maria Ilaria Del Principe,
  • Valter Gattei,
  • Riccardo Bomben

摘要

Chronic lymphocytic leukemia (CLL) cells may bear mutations in IGHV genes, the 2%-cutoff allowing to discriminate two subsets, unmutated (U)- or mutated (M)-CLL, with different clinical course. IGHV genes may also incorporate additional ongoing mutations, a phenomenon known as intraclonal diversification (ID). Here, through an original bioinformatic workflow for NGS data, we used the inverse Simpson Index (iSI) as diversity measure among IGHV sequences to dichotomize cases with different ID levels into IDhigh (iSI ≥ 1.2) vs. IDlow (iSI < 1.2) both in CLL (n = 983) and in other lymphoproliferative disorders (LPD; n = 127). In CLL, IDhigh cases accounted for 14.6%, overrepresented in M-CLL (P = 0.0028), while higher percentages were documented in GC-derived LPD. In M-CLL (n = 396), IDhigh patients (n = 69) experienced longer time-to-first treatment than IDlow patients (P = 0.015), and multivariate analyses (n = 299) confirmed ID as independent variable. IGHV gene mutations of IDhigh cases had molecular signatures indicating ongoing activity of the AID)/Polη-dependent machinery; consistently, IDhigh M-CLL expressed higher levels of AID transcripts than IDlow M-CLL (P = 0.012). In conclusion, we propose a robust NGS protocol to quantitatively evaluate ID in CLL, demonstrating that: i) all CLL patients presented ID although at various degree; ii) high degree of ID has clinical relevance identifying a M-CLL subset with better outcome.